This drug maker, 40% owned by MF & FPIs, just had a weak Q2. Time to sell?


The scrip has been a favourite of mutual funds and FPIs, who owned over 40 per cent stake in the drug maker, with promoters holding another 46.29 per cent stake, leaving non-institutional holding at 9.8 per cent. But the stock has hardly performed, falling 6 per cent year-to-date and delivering no return in the last one year.
Did you miss our previous article…
https://venox-invest.info/?p=528